Skip to content

A breast cancer 3D model derived from tissue biopsies

Biopsy derived Breast Cancer Organoids; “Assessing individualized therapy opportunities”

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON21020
Enrollment
30
Registered
2018-06-13
Start date
2018-10-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

Patients will undergo standard diagnostics and work-up according to the Dutch National Guidelines, including the marker placement procedure. During the marker placement procedure an accessory tumor ti

Sponsors

Maastricht University Medical Center +
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: - Female, - >18 years, - Breast cancer (proven by histopathology), - Undergoing the marker placement procedure.

Exclusion criteria

Exclusion criteria: - Physically or mentally incapable or incompetent to sign informed consent.

Design outcomes

Primary

MeasureTime frame
To develop a patient derived clinical model of breast (cancer) organoids using tissue biopsies.

Secondary

MeasureTime frame
Histological, genomic, and proteomic analysis will be conducted to provide insight in whether these organoids are patient representative and could result in patient tailored treatment. Furthermore, existing and newly developed therapies will be tested on this model - with the ultimate goal, to predict therapy response and/or resistance. Therapy efficacy will be assessed using viability assays, and genomic- and proteomic analysis.

Contacts

Public ContactM.L. Smidt

P.O. box 5800

m.smidt@mumc.nl+31 (0)433-877477

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)